Umbrage, a Houston-based developer of enterprise software, has been acquired. Photo via umbrage.com

A Houston software company is celebrating an exit this month.

Umbrage, founded in 2019, is proving once again that Space City is a software hub. Earlier this month, Founder Will Womble announced that Umbrage has been acquired by Bain & Company.

Umbrage creates custom software for companies by partnering with an internal technology team that makes the products. It’s a “teach a man to fish” method that has brought the company great success in creating software such as Shell’s TapUp app.

Bain & Company works with clients in 64 cities across 39 countries, meaning the global consultancy is positioned to bring Umbrage worldwide.

"Alongside Bain, we can deliver enhanced end-to-end solutions that will position our clients for success and to adapt during waves of disruptive emerging technologies," says CEO Womble in the release.

Bain’s Vector program has advised more than 6,700 digital projects around the world and across industries. It works by creating joint teams featuring Bain’s consulting staff, allowing companies to reach their digital goals themselves, but with a little help, not unlike Umbrage’s own methods. Acquiring Umbrage gives Bain a boost in its ability to help clients on a larger scale.

"Bain's commitment to delivering results with clients requires expanding and enhancing its ability to innovate and industrialize digital solutions," says Arpan Sheth, global leader of Vector, Bain's digital delivery platform. "Joining forces with Umbrage will allow us to develop a best-in-class, craft-centric digital product and venture building studio that will enable our clients to not only develop successful digital strategies, but to also execute on these strategies through world-class software capabilities. Umbrage further enhances Bain's Next solution to support our clients in their business building missions.”

Once the deal is completed, Umbrage will operate independently, but as a branded service line that’s part of Bain Innovation & Design. But existing clients needn’t worry. Umbrage will continue to assist them, including clients in financial services, energy, natural resources, and other industries.

In 2021, Umbrage raised a $2 million round led by Rice Investment Group. Womble previously joined the Houston Innovators Podcast to share how Houston has played a role in the company's growth.

Will Womble founded Umbrage in 2018. Photo courtesy

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.